Non-replicating rhabdovirus-derived particles (NRRPs) eradicate acute leukemia by direct cytolysis and induction of antitumor immunity

FieldValue
dc.contributor.authorBatenchuk, C
dc.contributor.authorLe Boeuf, F
dc.contributor.authorStubbert, L
dc.contributor.authorFalls, T
dc.contributor.authorAtkins, H L
dc.contributor.authorBell, J C
dc.contributor.authorConrad, D P
dc.date.accessioned2014-10-01T01:32:34Z
dc.date.available2014-10-01T01:32:34Z
dc.date.created2013
dc.date.issued2013
dc.identifier.citationBlood Cancer Journal (2013) 3, e123
dc.identifier.urihttp://hdl.handle.net/10393/31657
dc.identifier.urihttp://www.nature.com/bcj/journal/v3/n7/pdf/bcj201323a.pdf
dc.description.abstractRhabdoviruses (RVs) are currently being pursued as anticancer therapeutics for various tumor types, notably leukemia. However, modest virion production and limited spread between noncontiguous circulating leukemic cells requires high-dose administration of RVs, which exceeds the maximum tolerable dose of the live virus. Furthermore, in severely immunosuppressed leukemic patients, the potential for uncontrolled live virus spread may compromise the safety of a live virus approach. We hypothesized that the barriers to oncolytic virotherapy in liquid tumors may be overcome by administration of high-dose non-replicating RVs. We have developed a method to produce unique high-titer bioactive yet non-replicating rhabdovirus-derived particles (NRRPs). This novel biopharmaceutical is multimodal possessing direct cytolytic and immunomodulatory activity against acute leukemia. We demonstrate that NRRP resistance in normal cells is mediated by intact antiviral defences including interferon (IFN). This data was substantiated using murine models of blast crisis. The translational promise of NRRPs was demonstrated in clinical samples obtained from patients with high-burden multidrug-resistant acute myeloid leukemia. This is the first successful attempt to eradicate disseminated cancer using a non-replicating virus-derived agent, representing a paradigm shift in our understanding of oncolytic virus-based therapies and their application toward the treatment of acute leukemia.
dc.language.isoen
dc.subjectacute leukemia
dc.subjectoncolytic virus
dc.subjectnon-replicative rhabdovirus-derived particles
dc.subjectNRRP
dc.titleNon-replicating rhabdovirus-derived particles (NRRPs) eradicate acute leukemia by direct cytolysis and induction of antitumor immunity
dc.typeArticle
dc.identifier.doi10.1038/bcj.2013.23
CollectionPublications en libre accès financées par uOttawa // uOttawa financed open access publications

Files